Grifols (GRFS) Gains from Equity Investments (2010 - 2015)
Grifols (GRFS) posted Gains from Equity Investments of $4.0 million for Q3 2015, up 1255.84% quarter-over-quarter from -$346591.1 in Q2 2015.
Grifols (GRFS) Gains from Equity Investments (2010 - 2015) Analysis & Trends
Grifols (GRFS) has reported Gains from Equity Investments for 5 consecutive years, with $4.0 million the latest figure, recorded in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 4.01 Mn |
| Sep 30, 2015 | 4.01 Mn |
| Jun 30, 2015 | -346,591.09 |
| Jun 30, 2015 | -346,591.09 |
| Mar 31, 2015 | 355,897.24 |
| Mar 31, 2015 | 355,897.24 |
| Sep 30, 2014 | 3.89 Mn |
| Sep 30, 2014 | 3.89 Mn |
| Jun 30, 2014 | -2.16 Mn |
| Jun 30, 2014 | -2.16 Mn |
| Mar 31, 2014 | 2.17 Mn |
| Mar 31, 2014 | 2.17 Mn |
| Sep 30, 2013 | 381,611.12 |
| Sep 30, 2013 | 381,611.12 |
| Jun 30, 2013 | 1.36 Mn |
| Jun 30, 2013 | 1.36 Mn |
| Mar 31, 2013 | 357,815.36 |
| Mar 31, 2013 | 357,815.36 |
| Sep 30, 2012 | 490,238.98 |
| Sep 30, 2012 | 490,238.98 |